SCHEMBL2886259

SCHEMBL2886259

COc1ccc(-c2nn3cnnc3c3ccccc23)cn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
HTT P42858 3/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
MAPT P10636 7/20 0.42
POLB P06746 4/20 0.42
ATM Q13315 1/20 0.42
JAK2 O60674 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM4E B2RXH2 2/20 0.40
PKM P14618 2/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 2/20 0.40
ALPL P05186 1/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
KDR P35968 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2879800 0.78 HRH3 (0.48) ALDH1A1HTTMEN1KMT2AATM
SCHEMBL10662541 0.76 ALDH1A1 (0.77) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL13721774 0.72 PDE4A (0.43) ALDH1A1MEN1KMT2AJAK2KDM4E
SCHEMBL2879799 0.70 L3MBTL1 (0.41) ALDH1A1HTTMAPTNPSR1HPGD
SCHEMBL2888905 0.70 ALDH1A1 (0.52) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL2883455 0.69 ALDH1A1 (0.51) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL2885687 0.69 ALDH1A1 (0.51) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL8215862 0.67 KDR (0.48) MEN1KMT2AJAK2NPC1KDM4E
SCHEMBL2886889 0.67 PDE4A (0.60) ALDH1A1MAPTPOLBATMNPSR1
SCHEMBL23023549 0.67 JAK2 (0.51) MEN1KMT2AJAK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645756-B2 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases BANYU PHARMACEUTICAL CO. LTD. (JP) 2010-01-12 US disclosed
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative MSD K.K. (JP) 2007-07-19 US disclosed
EP-1719756-A1 NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative HRH3, HRH2, HRH4 ALDH1A1 1934/4885HTT 1027/4885MEN1 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.